Bill

Bill > HR4629


US HR4629

Star Rating for Biosimilars Act


summary

Introduced
10/08/2019
In Committee
10/09/2019
Crossed Over
Passed
Dead
12/31/2020

Introduced Session

116th Congress

Bill Summary

To amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to add a new set of measures to the 5-star rating system under the Medicare Advantage program in order to encourage increased access to biosimilar biological products. This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management. The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.

AI Summary

This bill, the Star Rating for Biosimilars Act, requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management. The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit. The goal is to encourage increased access to biosimilar biological products, which are lower-cost versions of brand-name biological drugs.

Committee Categories

Business and Industry, Health and Social Services

Sponsors (2)

Last Action

Sponsor introductory remarks on measure. (CR H8232) (on 10/18/2019)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...